Roberts Christopher D. 4
4 · Black Diamond Therapeutics, Inc. · Filed Feb 4, 2021
Insider Transaction Report
Form 4
Roberts Christopher D.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-02-03$10.86/sh+2,500$27,150→ 5,700 total - Sale
Common Stock
2021-02-03$25.35/sh−2,500$63,375→ 3,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-03−2,500→ 171,109 totalExercise: $10.86Exp: 2029-09-08→ Common Stock (2,500 underlying)
Footnotes (2)
- [F1]Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020.
- [F2]25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.